Health
DARE-19: No significant decrease in major events; dapagliflozin well tolerated in COVID-19 – Healio
The SGLT2 inhibitor dapagliflozin did not significantly reduce risk for organ failure or death or improve recovery among adults hospitalized with COVID-19 vs. placebo,…
Source/Disclosures
Source: Kosiborod M, et al. Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).
Disclosures:
The DARE-19 trial was funded by AstraZeneca. Kosiborod reports he received grants or advisory board, consultant or speaking fees from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk…
-
General17 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News23 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
General22 hours agoAustralia welcomes Gaza peace progress, hostage release
-
General15 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell